Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012 Nov;14(6):801-2.
doi: 10.1038/aja.2012.75. Epub 2012 Jul 30.

Mapping mutations in prostate cancer exomes

Benjamin Sunkel  1 , Qianben Wang
Affiliations
Comment

Mapping mutations in prostate cancer exomes

Benjamin Sunkel et al. Asian J Androl. 2012 Nov.

Abstract

Comprehensive identification of driver mutations in prostate cancer can serve to enhance our understanding of the disease and expand the use of available treatment options. Two recent and complementary studies from Barbieri et al.1 and Grasso et al.2 have reported the results of exome sequencing analysis in large cohorts of primary, treatment-naïve and lethal castration-resistant prostate cancer (CRPC) cases, respectively. Together, these analyses revealed a number of novel genetic mutations representing uncharacterized drivers as well as combinations of mutations that may define important prostate cancer subtypes.

PubMed Disclaimer

Comment on

  • Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.
    Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, Auclair D, Onofrio RC, Park K, Kitabayashi N, MacDonald TY, Sheikh K, Vuong T, Guiducci C, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Hussain WM, Ramos AH, Winckler W, Redman MC, Ardlie K, Tewari AK, Mosquera JM, Rupp N, Wild PJ, Moch H, Morrissey C, Nelson PS, Kantoff PW, Gabriel SB, Golub TR, Meyerson M, Lander ES, Getz G, Rubin MA, Garraway LA. Barbieri CE, et al. Nat Genet. 2012 May 20;44(6):685-9. doi: 10.1038/ng.2279. Nat Genet. 2012. PMID: 22610119 Free PMC article.
  • The mutational landscape of lethal castration-resistant prostate cancer.
    Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA. Grasso CS, et al. Nature. 2012 Jul 12;487(7406):239-43. doi: 10.1038/nature11125. Nature. 2012. PMID: 22722839 Free PMC article.

References

    1. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44:685–9. - PMC - PubMed
    1. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, et al. The mutational landscape of lethal castration-resistant prostate cancer Naturee-pub ahead of print 20 May 2012; doi:10.1038/nature11125. - PMC - PubMed
    1. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010;24:1967–2000. - PMC - PubMed
    1. Wu D, Zhang C, Shen Y, Nephew KP, Wang Q. Androgen receptor-driven chromatin looping in prostate cancer. Trends Endocrinol Metab. 2011;22:474–80. - PMC - PubMed
    1. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, et al. The genomic complexity of primary human prostate cancer. Nature. 2011;470:214–20. - PMC - PubMed

LinkOut - more resources